Trial
NCT03221842
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
CSL Behring
Collaborators
—
Condition
Antibody-mediated Rejection
Intervention
C1-esterase inhibitor
Why stopped
The study was terminated early due to futility of enrolment and not for safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-29